ProfileGDS5678 / 1420713_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 58% 56% 55% 56% 55% 54% 55% 55% 54% 72% 55% 55% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4325755
GSM967853U87-EV human glioblastoma xenograft - Control 23.5067758
GSM967854U87-EV human glioblastoma xenograft - Control 33.3982456
GSM967855U87-EV human glioblastoma xenograft - Control 43.3305555
GSM967856U87-EV human glioblastoma xenograft - Control 53.3782956
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4785455
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4265754
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3660955
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3503755
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3252354
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5293772
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3538955
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3848655
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3858555